Venture Kick

Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.

Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are unlocking the potential of glycomics and metabolomics in disease biomarker discovery and for the development of safer nutritional and pharmaceutical products.

Pace Locator's aim is to leverage the potential of common, noninvasive patient data to enable faster, more reliable diagnosis and, eventually, safer, more successful treatment.

Procavea Biotech specializes in developing a drug delivery platform centered on non-viral protein cages. This innovative platform is tailored for veterinary professionals, aiming to streamline and improve the efficiency of veterinary practice management. By providing a comprehensive solution, Procavea Biotech enhances overall operational effectiveness, enabling veterinary services to be delivered more seamlessly and integrated. Through its advancements, the company seeks to elevate the quality of care in veterinary practices.

HeroSupport is a medical device manufacturing company that transforms imaging and/or treatment tables into personalized solutions. The company was founded in 2019 and is headquartered in Veyrier, Geneva.

Orio Therapeutics is redefining regeneration by modifying therapeutic proteins to optimize distribution through controlled localization.

Rhovica Neuroimaging is a rapid and safe placement of an external ventricular drain (EVD) and is a lifesaving emergency procedure. EVDs are thin catheters, that are inserted into the brain cavities (ventricles) for fluid drainage to decrease intracranial pressure (ICP) and for measurement of ICP.

Ocumeda is a telemedical network specializing in ophthalmology, providing accessible eye examinations through collaborations with opticians, retirement homes, and various companies. The company's services include remote assessments conducted by board-certified ophthalmologists, utilizing a secure cloud platform and advanced medical artificial intelligence to enhance the screening process. This approach aims to enable opticians and pharmacies to effectively detect blindness and prevent vision loss, ensuring that individuals receive timely and accurate eye care.

SightIn Health develops artificial intelligence-powered software for using portable ultrasound. It provides image analytics, usage guidance, and interpretation of patient's diagnosis. SightIn Health was founded in 2021 and is based in Geneva, Switzerland.

FimmCyte is a biotechnology company focused on developing innovative disease-modifying treatments for fibro-inflammatory diseases, with an initial emphasis on endometriosis. The company aims to accelerate the journey toward effective cures by addressing significant healthcare needs and introducing novel solutions that enhance women's health. FimmCyte is dedicated to empowering women to take control of their health and tackle unmet medical needs associated with these conditions.

Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are unlocking the potential of glycomics and metabolomics in disease biomarker discovery and for the development of safer nutritional and pharmaceutical products.

OptimaRatio liberates chronic and rare disease patients from managing their complex health data.

Avelo mission is to save lives by bringing fast and actionable infectious disease diagnoses to primary care.

NexMR is a Swiss company offering key-in-hand solutions to improve the throughput and optimize the resources of NMR-drug discovery pipelines. NexMR’s technology is designed to be accessible to the most and to ease the addressing of challenging targets.

Rhovica Neuroimaging is a rapid and safe placement of an external ventricular drain (EVD) and is a lifesaving emergency procedure. EVDs are thin catheters, that are inserted into the brain cavities (ventricles) for fluid drainage to decrease intracranial pressure (ICP) and for measurement of ICP.

Simulatory is a developer of a virtual simulator aimed at training surgeons in ultra-minimally invasive endoscopic techniques for spinal surgery. The simulator offers an intuitive workspace and a simulation guide that leverages machine learning and artificial intelligence, allowing surgeons to practice in a safe, data-driven environment. This innovative approach enhances surgical training by providing realistic scenarios that prepare surgeons for complex procedures, ultimately improving patient outcomes in spinal surgery.

NexMR is a Swiss company offering key-in-hand solutions to improve the throughput and optimize the resources of NMR-drug discovery pipelines. NexMR’s technology is designed to be accessible to the most and to ease the addressing of challenging targets.

Rhovica Neuroimaging is a rapid and safe placement of an external ventricular drain (EVD) and is a lifesaving emergency procedure. EVDs are thin catheters, that are inserted into the brain cavities (ventricles) for fluid drainage to decrease intracranial pressure (ICP) and for measurement of ICP.

Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and nanofluidics.

Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at the early detection of cachexia, a serious condition characterized by severe body wasting. The company has created a first-in-class CT contrast product that allows for the detection of body wasting prior to noticeable weight loss, potentially up to a year earlier. This advancement enables healthcare providers to identify cancer at an earlier stage, ultimately improving patient outcomes and enhancing their quality of life. By facilitating timely intervention, Adiposs aims to provide patients with a better chance of survival against cancer and other chronic illnesses.

Bottneuro specializes in developing non-invasive therapies for patients with early to moderate-stage Alzheimer's Disease. The company utilizes its NENI technology platform to create stimulation protocols that employ electrical stimulation of neurons and glial cells in the brain. Additionally, Bottneuro's innovative brain therapy system incorporates plant-based components and features a 3D-printed cap designed for continuous monitoring and targeted delivery of active substances. This approach aims to address the specific needs of Alzheimer's patients, ultimately enhancing their quality of life and improving treatment outcomes.

InnoSpina specializes in the design and development of innovative 3D printed implants and surgical guiding instruments aimed at treating chronic back pain efficiently. The company focuses on creating minimally invasive and motion-preserving technologies for spinal disorders. Its products are designed to empower spine surgeons and interventional pain management specialists by providing safe, intuitive instruments that facilitate accurate positioning of implants. This approach simplifies surgical procedures and significantly reduces operative time, allowing surgeons to address chronic back pain in less than 30 minutes.

Resmonics, established in October 2020 as a spin-off from ETH Zürich and the University of St. Gallen, specializes in privacy-friendly acoustic artificial intelligence designed to analyze soundscapes in various environments. Its primary focus is on detecting symptoms of infectious lung diseases, particularly for chronic disease management and monitoring respiratory symptoms. The company's flagship product line, Quorum, integrates this AI technology with air quality sensors and noise analytics to foster healthy and productive working conditions. Additionally, Resmonics develops tools that provide objective, clinically validated insights into respiratory health, offering early warnings for potential crises and enhancing patient care through mobile applications.

Abologix is a biopharmaceutical company focused on developing innovative therapies for oncology. The company specializes in creating monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. This treatment aims to provide options for patients who do not respond to conventional cancer therapies, addressing various oncological conditions. By advancing its research in this area, Abologix seeks to enhance treatment outcomes and improve the quality of care for cancer patients.

Bone fractures involving a joint are complex in nature, resulting in difficult and time-consuming procedures for the treating orthopaedic surgeon. We provide fracture specific optimization of complex bone reconstruction. Our software solution ensures efficacy of personalized surgical planning, as well as “save and effective” patient-specific implant and instrument design, changing the treatment strategy from a subjective to an objective approach with more predictable outcomes. This could improve outcomes of 400,000 trauma patients, addressing a $1.2 B market. A Harvard Medical School surgeon directing the medical aspects, provides crucial credibility.

aiEndoscopic is a MedTech start-up focused on enhancing the safety and simplicity of tracheal intubations through the integration of robotic endoscopy and artificial intelligence. The company designs intelligent medical equipment that combines visual access and precision to facilitate assistive and potentially autonomous endoscopy. This innovative approach aims to empower surgeons to perform intubations and other surgical procedures more effectively, ultimately reducing risks to patients' lives. With a commitment to improving surgical outcomes, aiEndoscopic strives to revolutionize the field of endoscopy by making advanced medical technology more accessible and user-friendly for healthcare professionals.

Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.

Bone fractures involving a joint are complex in nature, resulting in difficult and time-consuming procedures for the treating orthopaedic surgeon. We provide fracture specific optimization of complex bone reconstruction. Our software solution ensures efficacy of personalized surgical planning, as well as “save and effective” patient-specific implant and instrument design, changing the treatment strategy from a subjective to an objective approach with more predictable outcomes. This could improve outcomes of 400,000 trauma patients, addressing a $1.2 B market. A Harvard Medical School surgeon directing the medical aspects, provides crucial credibility.

Abologix is a biopharmaceutical company focused on developing innovative therapies for oncology. The company specializes in creating monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. This treatment aims to provide options for patients who do not respond to conventional cancer therapies, addressing various oncological conditions. By advancing its research in this area, Abologix seeks to enhance treatment outcomes and improve the quality of care for cancer patients.

Axentless develops software using advanced algorithmic technologies to enable interactive speech therapy practice for stroke victims.

Eldico Scientific AG, founded in 2019 and based in Villigen, Switzerland, specializes in the development and manufacturing of electron diffractometers designed for the analysis of solid compounds. The company's innovative instruments enable researchers in various fields, including pharmaceuticals, agrochemicals, and advanced materials, to characterize nano-crystalline systems that were previously difficult to measure. By providing tools for nano-crystallographic investigations, Eldico aims to enhance the efficiency and cost-effectiveness of structural information gathering, thereby accelerating the drug discovery and development process. The company has made significant strides in the field, achieving proof of concept for its technology in collaboration with leading Swiss research institutions, and has received recognition for its contributions to scientific advancement.

Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at the early detection of cachexia, a serious condition characterized by severe body wasting. The company has created a first-in-class CT contrast product that allows for the detection of body wasting prior to noticeable weight loss, potentially up to a year earlier. This advancement enables healthcare providers to identify cancer at an earlier stage, ultimately improving patient outcomes and enhancing their quality of life. By facilitating timely intervention, Adiposs aims to provide patients with a better chance of survival against cancer and other chronic illnesses.

Nutrix is a Swiss health-tech company founded in 2019 and based in Basel. It specializes in developing a nanosensor that is placed on the tooth to measure glucose levels in saliva, providing a non-invasive method for users to monitor their health. This technology is integrated with an external application that tracks food intake and offers dietary advice, aiming to aid in the prevention of diabetes. Nutrix combines artificial intelligence with wearables to create cost-effective healthcare solutions. In 2025, the company plans to introduce CortiSense, a non-invasive cortisol monitoring sensor that has already received a CES Innovation Award, further expanding its portfolio of health monitoring technologies. Through its innovative approach, Nutrix enables users to manage their health conditions effectively without the need for frequent medical consultations.

Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.

MimiX Biotherapeutics Sàrl, established in 2016 and based in La Tène, Switzerland, specializes in the development of biofabrication technology for therapeutic and diagnostic applications. The company focuses on creating an ultra-fast biomanufacturing process that enables the production of patient-specific biological tissue equivalents. This innovative approach supports regenerative medicine and personalized healthcare, allowing for tailored treatments that meet individual patient needs. By advancing tissue engineering techniques, MimiX Biotherapeutics aims to enhance the precision and effectiveness of medical interventions.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company focuses on developing therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. A significant portion of time in intensive care is dedicated to weaning patients off ventilators and restoring diaphragm function, which is critical for independent breathing. STIMIT's technology non-invasively activates the diaphragm, helping to keep it strong and functional, ultimately aiming to liberate patients from ventilators and reduce associated morbidity and mortality. Additionally, STIMIT is advancing a proprietary method for localized delivery of cancer immunotherapy, enhancing the efficacy and safety of treatment for patients with solid tumors. This dual focus positions STIMIT at the forefront of innovation in both respiratory care and oncology.

SurgeonsLab, founded in 2020 and based in Bern, Switzerland, specializes in developing patient-specific training models for surgical procedures and the validation of new medical devices. The company focuses on microsurgical treatment planning and strategy, providing tools that enhance the training experience for medical professionals. By utilizing advanced technology, SurgeonsLab's products facilitate testing and planning for surgical interventions, significantly improving patient safety and outcomes. The company's innovative approach offers an alternative to traditional human and animal models, thereby enhancing the learning curve for medical trainees.

Selph is a medical technology company that focuses on developing a medical device that enables people to conduct a self-test for sexually transmitted diseases. It specializes in digital health, sensors, diagnostics, and medical services.

Inanna builds clinical decision support solutions for fertility clinics. We are uniquely positioned to provide the worldwide first holistic algorithm-based support tool covering all critical decisions along the treatment path.

Terapet was founded at CERN by two physicists – Christina Vallgren and Marcus Palm – along with Professor Raymond Miralbell from the Geneva University Hospitals (HUG). They have already proven the feasibility of their concept and are now developing an initial version for market launch.

Testmate Health is a medtech startup and an award-winning spin-off of the University of Geneva, focused on developing innovative healthcare solutions. The company has created a smartphone-compatible test kit that can diagnose diseases with identifiable DNA or RNA sequences, providing results directly at home in just minutes. Its first product is a rapid urine self-test for the four most common sexually transmitted diseases, addressing the urgent need for timely diagnosis, as one million new STDs are diagnosed daily. Traditional testing often requires lab work and can take up to seven days for results. Testmate Health's all-in-one kit is designed for ease of use, allowing users to obtain immediate results that can be scanned by a smartphone for quick access to treatment if necessary. The company is also working on additional test kits for other diseases, aiming to empower individuals to manage their health conveniently from home.

Swiss Medical Union SA, founded in 2019 and based in Yverdon-les-Bains, Switzerland, specializes in healthcare technology focused on testing the interaction, efficiency, and safety of new medical products. The company manufactures Micro-Bioreactor equipment that allows for ex vivo testing with human organ and tissue models, enabling the selection of appropriate therapies tailored to individual patient needs. Additionally, Swiss Medical Union develops software that simulates organ activity, analyzes interactions between medical products and specific organs, and monitors real-time effects of treatments within the circulatory system. The company also provides clinical testing services aimed at supporting healthcare professionals in making informed clinical decisions, particularly in cancer treatment. Its offerings are designed to enhance therapeutic outcomes while minimizing the risks associated with unnecessary treatments.

MaxWell Biosystems AG is an electronics and biotechnology company based in Zurich, Switzerland, dedicated to advancing neuroscience research and enhancing preclinical drug discovery. Founded in 2016, the company specializes in functional cell imaging platforms, most notably its MaxOne electrophysiology platform. This innovative system features a high-density microelectrode array with 26,400 electrodes and 1,024 low-noise readout channels, which allows for precise recording and stimulation of electrogenic cells in vitro. By enabling researchers to extract detailed single cell and network parameters, MaxWell's technology significantly accelerates the characterization of cellular functions, reducing the typical timeframe from several months to just a few weeks. This advancement aids in phenotypic screening as well as drug toxicity and efficacy testing.

Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at the early detection of cachexia, a serious condition characterized by severe body wasting. The company has created a first-in-class CT contrast product that allows for the detection of body wasting prior to noticeable weight loss, potentially up to a year earlier. This advancement enables healthcare providers to identify cancer at an earlier stage, ultimately improving patient outcomes and enhancing their quality of life. By facilitating timely intervention, Adiposs aims to provide patients with a better chance of survival against cancer and other chronic illnesses.

Anavo Medical specializes in developing nanoparticle-based pharmaceutical products aimed at enhancing wound healing and minimizing complications associated with skin grafts. The company's innovative formulation utilizes bioactive nanoparticles suspended in a user-friendly matrix, incorporating active ingredients such as metal oxide nanoparticles. These components possess anti-inflammatory and neo-angiogenic properties, which stimulate blood vessel regeneration and mitigate inflammation. By leveraging advanced nanotechnology, Anavo Medical's products empower healthcare professionals to improve patient outcomes, ensuring safer surgeries and promoting faster recovery for individuals undergoing skin transplantation procedures.

Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders. The company also develops breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of the natural functioning of the brain. The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the bran. There is a high demand for new pharmacological treatments in this area especially for certain diseases such as post-traumatic stress disorder (PTSD) which has a high unmet medical need.

KaleiBox is inspired by the optical toy of kaleidoscope, emphasizing its versatility, portability and beauty. Combining compact hardware and sophisticated software, KaleiBox is expected to complement the current workflow of 3D fluorescence imaging, especially in the scenario of preclinical imaging.

Eldico Scientific AG, founded in 2019 and based in Villigen, Switzerland, specializes in the development and manufacturing of electron diffractometers designed for the analysis of solid compounds. The company's innovative instruments enable researchers in various fields, including pharmaceuticals, agrochemicals, and advanced materials, to characterize nano-crystalline systems that were previously difficult to measure. By providing tools for nano-crystallographic investigations, Eldico aims to enhance the efficiency and cost-effectiveness of structural information gathering, thereby accelerating the drug discovery and development process. The company has made significant strides in the field, achieving proof of concept for its technology in collaboration with leading Swiss research institutions, and has received recognition for its contributions to scientific advancement.

4i Labs generates multiplexed images of biological samples for molecular view of tumours.

OxyPrem AG is a Swiss company that specializes in developing and manufacturing sensor solutions for monitoring preterm infants. Founded in 2018 and based in Zurich, OxyPrem offers an advanced reusable oxygen sensor that continuously measures brain oxygen levels in high-risk preterm infants using noninvasive near-infrared light technology. This device accurately determines hemoglobin oxygen saturation in any human tissue, allowing healthcare providers to deliver improved clinical care while significantly reducing waste. By enabling real-time monitoring, OxyPrem's technology plays a crucial role in preventing early death and mitigating the risk of severe long-term brain damage in this vulnerable population.

Microcaps AG is a company based in Zurich, Switzerland, specializing in the development of innovative microencapsulation technology. Founded in 2018, it focuses on creating a scalable production system for precise microcapsules and microparticles using advanced microfluidics. The company's devices enable the fabrication of monodisperse capsules and emulsions of various sizes, providing tailored solutions for drug delivery, probiotic encapsulation, and enhancing the stability of pharmaceutical agents and fragrances in cosmetic products. Microcaps aims to offer a fully automated encapsulation micro-factory that ensures size control and precise dosing, significantly improving production efficiency and throughput rates compared to conventional methods.

OxyPrem AG is a Swiss company that specializes in developing and manufacturing sensor solutions for monitoring preterm infants. Founded in 2018 and based in Zurich, OxyPrem offers an advanced reusable oxygen sensor that continuously measures brain oxygen levels in high-risk preterm infants using noninvasive near-infrared light technology. This device accurately determines hemoglobin oxygen saturation in any human tissue, allowing healthcare providers to deliver improved clinical care while significantly reducing waste. By enabling real-time monitoring, OxyPrem's technology plays a crucial role in preventing early death and mitigating the risk of severe long-term brain damage in this vulnerable population.

Endotelix is a Swiss biotech start-up and a spin-off from the University of Geneva, focused on developing innovative solutions for Antiphospholipid Syndrome. The company specializes in creating fast, sensitive, and reliable diagnostic tests and treatment options aimed at detecting circulating antibodies associated with this condition. Endotelix primarily targets the healthcare needs of pregnant women and adolescent children, providing research tools and therapies that assist healthcare professionals in reducing pregnancy-related complications and enhancing overall healthcare outcomes.

Alibion AG, founded in 2018 and based in Allschwil, Switzerland, specializes in drug discovery and the development of therapeutics. The company addresses the challenge of bringing innovative therapies from academic laboratories to patients by accelerating early-stage development. Alibion focuses on identifying promising new therapeutics and collaborates with outsourced partners to streamline the development process, thereby minimizing time and costs while ensuring compliance with quality standards. By doing so, Alibion aims to enhance the availability of novel treatments, ultimately improving patient outcomes on a global scale.

Anavo Medical specializes in developing nanoparticle-based pharmaceutical products aimed at enhancing wound healing and minimizing complications associated with skin grafts. The company's innovative formulation utilizes bioactive nanoparticles suspended in a user-friendly matrix, incorporating active ingredients such as metal oxide nanoparticles. These components possess anti-inflammatory and neo-angiogenic properties, which stimulate blood vessel regeneration and mitigate inflammation. By leveraging advanced nanotechnology, Anavo Medical's products empower healthcare professionals to improve patient outcomes, ensuring safer surgeries and promoting faster recovery for individuals undergoing skin transplantation procedures.

Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at the early detection of cachexia, a serious condition characterized by severe body wasting. The company has created a first-in-class CT contrast product that allows for the detection of body wasting prior to noticeable weight loss, potentially up to a year earlier. This advancement enables healthcare providers to identify cancer at an earlier stage, ultimately improving patient outcomes and enhancing their quality of life. By facilitating timely intervention, Adiposs aims to provide patients with a better chance of survival against cancer and other chronic illnesses.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company focuses on developing therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. A significant portion of time in intensive care is dedicated to weaning patients off ventilators and restoring diaphragm function, which is critical for independent breathing. STIMIT's technology non-invasively activates the diaphragm, helping to keep it strong and functional, ultimately aiming to liberate patients from ventilators and reduce associated morbidity and mortality. Additionally, STIMIT is advancing a proprietary method for localized delivery of cancer immunotherapy, enhancing the efficacy and safety of treatment for patients with solid tumors. This dual focus positions STIMIT at the forefront of innovation in both respiratory care and oncology.

Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders. The company also develops breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of the natural functioning of the brain. The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the bran. There is a high demand for new pharmacological treatments in this area especially for certain diseases such as post-traumatic stress disorder (PTSD) which has a high unmet medical need.

Endotelix is a Swiss biotech start-up and a spin-off from the University of Geneva, focused on developing innovative solutions for Antiphospholipid Syndrome. The company specializes in creating fast, sensitive, and reliable diagnostic tests and treatment options aimed at detecting circulating antibodies associated with this condition. Endotelix primarily targets the healthcare needs of pregnant women and adolescent children, providing research tools and therapies that assist healthcare professionals in reducing pregnancy-related complications and enhancing overall healthcare outcomes.

Hi-D Imaging AG, founded in 2019 and based in Winterthur, Switzerland, specializes in a SaaS-based pre-operational planning platform tailored for cardiac procedures, particularly trans-catheter aortic valve implantation. The platform assesses the hemodynamics of patient-specific anatomies, allowing physicians to analyze blood flow patterns and perform in-vitro fluid dynamic analyses. This technology enables the selection of the optimal size and shape of heart valves, facilitating personalized solutions for patients with aortic stenosis before cardiac surgery. By streamlining pre-operational planning and enhancing data-driven decision-making, Hi-D Imaging aims to improve outcomes for patients with cardiovascular diseases while reducing the need for unnecessary medical imaging examinations. The company's AI-based cardiac image processing technology further supports medical professionals by producing detailed images of cardiac structures, thereby decreasing planning times and addressing the limitations of traditional medical scans.

B-rayZ is a spin-off from the University Hospital Zurich, focused on enhancing radiology through advanced technology. The team comprises experienced radiologists, data scientists, and physicians with over 15 years of expertise in medical imaging. B-rayZ develops artificial intelligence-based software that aids radiologists in mammography by offering real-time assessments of image quality and breast density. This innovative software enables accurate and standardized evaluations of medical imaging data, thereby improving breast cancer detectability. By providing intelligent tools, B-rayZ supports radiologists in enhancing their diagnostic capabilities while also contributing to reduced healthcare costs.

Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders. The company also develops breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of the natural functioning of the brain. The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the bran. There is a high demand for new pharmacological treatments in this area especially for certain diseases such as post-traumatic stress disorder (PTSD) which has a high unmet medical need.

OxyPrem AG is a Swiss company that specializes in developing and manufacturing sensor solutions for monitoring preterm infants. Founded in 2018 and based in Zurich, OxyPrem offers an advanced reusable oxygen sensor that continuously measures brain oxygen levels in high-risk preterm infants using noninvasive near-infrared light technology. This device accurately determines hemoglobin oxygen saturation in any human tissue, allowing healthcare providers to deliver improved clinical care while significantly reducing waste. By enabling real-time monitoring, OxyPrem's technology plays a crucial role in preventing early death and mitigating the risk of severe long-term brain damage in this vulnerable population.

Microcaps AG is a company based in Zurich, Switzerland, specializing in the development of innovative microencapsulation technology. Founded in 2018, it focuses on creating a scalable production system for precise microcapsules and microparticles using advanced microfluidics. The company's devices enable the fabrication of monodisperse capsules and emulsions of various sizes, providing tailored solutions for drug delivery, probiotic encapsulation, and enhancing the stability of pharmaceutical agents and fragrances in cosmetic products. Microcaps aims to offer a fully automated encapsulation micro-factory that ensures size control and precise dosing, significantly improving production efficiency and throughput rates compared to conventional methods.

SEED Biosciences are a Swiss award-winning startup providing innovative solutions for your single cell assays.

Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.

MOMM Diagnostics is a Swiss company founded in 2018 and headquartered in Basel. It specializes in the development of an in-vitro diagnostic test aimed at the early diagnosis of preeclampsia, a serious condition that can affect pregnant women. The company's innovative diagnostic device is designed for use at the point of care, allowing for quicker diagnosis and intervention, thereby improving patient outcomes. By focusing on women's health, MOMM Diagnostics aims to provide essential support to healthcare providers and enhance the care of pregnant women experiencing potential complications.

OxyPrem AG is a Swiss company that specializes in developing and manufacturing sensor solutions for monitoring preterm infants. Founded in 2018 and based in Zurich, OxyPrem offers an advanced reusable oxygen sensor that continuously measures brain oxygen levels in high-risk preterm infants using noninvasive near-infrared light technology. This device accurately determines hemoglobin oxygen saturation in any human tissue, allowing healthcare providers to deliver improved clinical care while significantly reducing waste. By enabling real-time monitoring, OxyPrem's technology plays a crucial role in preventing early death and mitigating the risk of severe long-term brain damage in this vulnerable population.

Volumina Medical SA is a Swiss company specializing in the development, manufacturing, and commercialization of tissue reconstruction technologies for the reconstructive and plastic surgery markets. It focuses on tissue engineering and has created injectable 3D scaffolds designed to reconstruct soft tissue volumes lost due to tumor ablation, disease, trauma, or for aesthetic reasons. These innovative scaffolds can be injected through thin cannulas, which helps to minimize both intervention and recovery times for patients. Volumina Medical aims to address the challenges associated with the natural repair of soft tissues, offering solutions that enhance surgical outcomes.

Clemedi AG develops innovative diagnostic workflows for infectious diseases, focusing on in vitro diagnostic tests that leverage next-generation sequencing and machine learning technologies. Established in 2018 and headquartered in Schlieren, Switzerland, the company aims to combat antibiotic resistance, which is projected to cause 10 million deaths annually by 2050. Clemedi's test kits are designed to diagnose drug-resistant infections directly from patient samples within a day, thereby enhancing doctors' decision-making and facilitating timely, personalized antibiotic therapies. By providing comprehensive information for targeted treatment, Clemedi strives to reduce antibiotic consumption and slow the spread of resistance, ultimately benefiting patients suffering from infectious diseases.

Qnami AG is a Swiss company established in 2017, specializing in the development of quantum sensing technologies for nanoscale imaging. The company manufactures non-invasive sensors, including the ProteusQ magnetic imaging microscope and the Quantum Diamond product line, which features diamond probes with single nitrogen-vacancy (NV) centers for high-resolution magnetic imaging. These advanced technologies enable the measurement of electric and magnetic fields with exceptional sensitivity, facilitating a range of applications such as the characterization of magnetic random-access memory (MRAM), imaging of proteins, and fundamental studies of superconductors. Qnami's innovations unlock new possibilities in both scientific research and industrial applications, aiming to enhance understanding and improve various aspects of life and technology.

SEED Biosciences are a Swiss award-winning startup providing innovative solutions for your single cell assays.

ONtrack Diagnostics is a medical technology company based in Zurich, Switzerland, that specializes in the development of non-invasive assays aimed at the screening, diagnosis, and monitoring of cancer. The company's initial product is a urine assay designed specifically for the screening of prostate cancer, reflecting its commitment to advancing cancer detection methods. Through its innovative approaches, ONtrack Diagnostics seeks to improve patient outcomes in the field of oncology.

Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.

Mirrakoi SA is a Swiss company established in 2018 and is a spin-off from the Swiss Federal Institute of Technology in Lausanne. It specializes in developing computer-aided design software, particularly focused on the medical field. The company's flagship product, Rhino3DMedical, facilitates a seamless workflow that allows users to view, analyze, and segment medical images, ultimately enabling the creation of 3D-printable meshes and CAD models from CT and MRI scans. This proprietary software is designed with a user-friendly interface, making it accessible for orthopedic surgical planning and the production of patient-specific anatomical models. Mirrakoi's innovative technology streamlines the process of generating anatomical 3D prints, enhancing both efficiency and precision in medical applications.

Volumina Medical SA is a Swiss company specializing in the development, manufacturing, and commercialization of tissue reconstruction technologies for the reconstructive and plastic surgery markets. It focuses on tissue engineering and has created injectable 3D scaffolds designed to reconstruct soft tissue volumes lost due to tumor ablation, disease, trauma, or for aesthetic reasons. These innovative scaffolds can be injected through thin cannulas, which helps to minimize both intervention and recovery times for patients. Volumina Medical aims to address the challenges associated with the natural repair of soft tissues, offering solutions that enhance surgical outcomes.

Clemedi AG develops innovative diagnostic workflows for infectious diseases, focusing on in vitro diagnostic tests that leverage next-generation sequencing and machine learning technologies. Established in 2018 and headquartered in Schlieren, Switzerland, the company aims to combat antibiotic resistance, which is projected to cause 10 million deaths annually by 2050. Clemedi's test kits are designed to diagnose drug-resistant infections directly from patient samples within a day, thereby enhancing doctors' decision-making and facilitating timely, personalized antibiotic therapies. By providing comprehensive information for targeted treatment, Clemedi strives to reduce antibiotic consumption and slow the spread of resistance, ultimately benefiting patients suffering from infectious diseases.

MotionTech is a company having developed a unique silicone 3D printing technology. Thanks to that, MotionTech now aims at bringing digitalisation to the orthopaedic world. They offer the "Your Liner" service, that allows prosthetic technician all around the world to order tailored silicone equipment, for their patient. Their goal is to drive a paradigm shift in the orthopaedic world, away from mass production and towards mass customisation.

SEED Biosciences are a Swiss award-winning startup providing innovative solutions for your single cell assays.

ABCDx SA is a Swiss company founded in 2014 that specializes in the development, validation, and application of biomarker tests for brain injury treatment. The company focuses on creating biomarker panels designed to identify and diagnose patients at risk for severe long-term complications resulting from conditions such as traumatic brain injuries, strokes, and post-stroke infections. The founders are prominent researchers from the University of Geneva and the Vall d’Hebron Research Institute, bringing significant expertise in biomarker discovery and clinical application. They are complemented by a third founder with extensive experience in the diagnostic and pharmaceutical industries, enhancing the company’s capacity to innovate in brain health diagnostics.

REM Analytics accurately addresses the Microtype of people for the microbiome industry. The company provides this measurement as an analytical service allowing customers to improve the impact of their products. The company has the unique capability to measure the colonization of specific probiotic strain in the microbiome of people. It can also measure the effectiveness of these strains on the micro type at large, as well as differences induced by changes in food and lifestyle. The company's objective is to allow the development of Evidence-based, personalized microbiome-based treatments.

SNAQ GmbH, based in Zurich, Switzerland, offers a mobile application that utilizes machine learning and computer vision technology to recognize food items and calculate portion sizes from images. By linking this information with a comprehensive nutrition database, the application provides users with detailed nutritional information, including carbohydrate, calorie, and protein content of their meals. SNAQ's innovative solution has been showcased at various diabetes conferences across Europe, emphasizing its relevance in the medical field and its potential to support health and lifestyle management.

Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.

RetinAI optimises and simplifies clinics, research and pharmaceutical workflows to improve healthcare. To achieve this goal, the company builds tools to collect, analyze and organize health data, empowering healthcare professionals and patients with automatic image and data analysis supported by advanced machine learning. RetinAI has proprietary technology that provides unforeseen image quality enhancement, as well as automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies and device manufacturers at similar level of performance as a human would produce.

APERI pharmaceuticals is a biotech in the launch phase developed around an oral biologics delivery platform. With already 2 patents filed and about 7 years of specific research and development we initially target the lucrative Rheumatoid arthritis market with an oral formulation of Adalimumab antibody (Humira). AP09 is a novel permeation enhancer and forms the cornerstone of our technology. It allows macromolecules to diffuse through the tight space between cells, known as tight junctions, where they won’t do it under normal conditions. AP09 adopts a unique, mechanism-based, target selective, trans-mucosal permeation enhancers that offer maximum safety index, highly reversible effect and can transport antibodies without causing any toxicity.

Mirrakoi SA is a Swiss company established in 2018 and is a spin-off from the Swiss Federal Institute of Technology in Lausanne. It specializes in developing computer-aided design software, particularly focused on the medical field. The company's flagship product, Rhino3DMedical, facilitates a seamless workflow that allows users to view, analyze, and segment medical images, ultimately enabling the creation of 3D-printable meshes and CAD models from CT and MRI scans. This proprietary software is designed with a user-friendly interface, making it accessible for orthopedic surgical planning and the production of patient-specific anatomical models. Mirrakoi's innovative technology streamlines the process of generating anatomical 3D prints, enhancing both efficiency and precision in medical applications.

Volumina Medical SA is a Swiss company specializing in the development, manufacturing, and commercialization of tissue reconstruction technologies for the reconstructive and plastic surgery markets. It focuses on tissue engineering and has created injectable 3D scaffolds designed to reconstruct soft tissue volumes lost due to tumor ablation, disease, trauma, or for aesthetic reasons. These innovative scaffolds can be injected through thin cannulas, which helps to minimize both intervention and recovery times for patients. Volumina Medical aims to address the challenges associated with the natural repair of soft tissues, offering solutions that enhance surgical outcomes.

Aesyra SA, founded in 2017 and based in Lausanne, Switzerland, specializes in the design and manufacture of medical devices focused on managing sleep disorders. The company's flagship product, AesyBite, is an intra-oral sensor that monitors and alleviates sleep bruxism, a condition characterized by teeth grinding during sleep. Aesyra's technology enables dental professionals to conduct intraoral measurements while patients sleep, allowing for the detection of bruxism and other sleep-related issues, such as obstructive sleep apnea. By providing accurate monitoring and biofeedback alternatives, Aesyra aims to help healthcare providers reduce damage to dental prostheses caused by occlusal problems and improve overall sleep quality for their patients.

Qnami AG is a Swiss company established in 2017, specializing in the development of quantum sensing technologies for nanoscale imaging. The company manufactures non-invasive sensors, including the ProteusQ magnetic imaging microscope and the Quantum Diamond product line, which features diamond probes with single nitrogen-vacancy (NV) centers for high-resolution magnetic imaging. These advanced technologies enable the measurement of electric and magnetic fields with exceptional sensitivity, facilitating a range of applications such as the characterization of magnetic random-access memory (MRAM), imaging of proteins, and fundamental studies of superconductors. Qnami's innovations unlock new possibilities in both scientific research and industrial applications, aiming to enhance understanding and improve various aspects of life and technology.

IbtiCare specializes in advanced antibacterial technology that utilizes Physical Vapor Deposition (PVD) to create coatings with nanoparticles that render surfaces antibacterial. This innovative solution effectively targets and eliminates a broad spectrum of dangerous bacteria, including those resistant to conventional drugs. The technology is designed to be fast-reactive, durable, and stable, ensuring long-lasting protection for various surfaces. IbtiCare's antibacterial solution has successfully passed clinical trials and has received validation from leaders in the healthcare sector, positioning it as a superior alternative to traditional antibacterial methods. The company's mission is to combat bacterial infections and enhance safety across multiple environments.

RetinAI optimises and simplifies clinics, research and pharmaceutical workflows to improve healthcare. To achieve this goal, the company builds tools to collect, analyze and organize health data, empowering healthcare professionals and patients with automatic image and data analysis supported by advanced machine learning. RetinAI has proprietary technology that provides unforeseen image quality enhancement, as well as automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies and device manufacturers at similar level of performance as a human would produce.

MotionTech is a company having developed a unique silicone 3D printing technology. Thanks to that, MotionTech now aims at bringing digitalisation to the orthopaedic world. They offer the "Your Liner" service, that allows prosthetic technician all around the world to order tailored silicone equipment, for their patient. Their goal is to drive a paradigm shift in the orthopaedic world, away from mass production and towards mass customisation.

Gnubiotics Sciences SA specializes in developing microbiome-modulating products aimed at nurturing, maintaining, and restoring microbiome diversity in humans and animals. Founded in 2016 and based in Epalinges, Switzerland, the company produces glycans and functional mimics of Human Milk Oligosaccharides (HMOs) for the consumer health market. Their flagship product, AMObiomeTM, is designed to enhance microbiome diversity and promote lifelong gut health. By replicating the natural structures found in breast milk, Gnubiotics aims to prevent infections and combat diet-induced obesity, while also addressing the growing demand for healthier food options. The company's innovative approach focuses on supporting immune systems and overall well-being through natural microbiome modulation.

MaxWell Biosystems AG is an electronics and biotechnology company based in Zurich, Switzerland, dedicated to advancing neuroscience research and enhancing preclinical drug discovery. Founded in 2016, the company specializes in functional cell imaging platforms, most notably its MaxOne electrophysiology platform. This innovative system features a high-density microelectrode array with 26,400 electrodes and 1,024 low-noise readout channels, which allows for precise recording and stimulation of electrogenic cells in vitro. By enabling researchers to extract detailed single cell and network parameters, MaxWell's technology significantly accelerates the characterization of cellular functions, reducing the typical timeframe from several months to just a few weeks. This advancement aids in phenotypic screening as well as drug toxicity and efficacy testing.

MesenFlow Technologies specializes in bio-imaging technology aimed at enhancing drug and cosmetic development. The company has created a platform that accelerates the drug development process by addressing challenges related to species cross-reactivity, animal testing, and understanding human diseases. Utilizing proprietary protocols on primary human cells, MesenFlow enables early definition of a drug's mechanism of action and translational relevance. The technology has also been adapted for the cosmetics and nutrition sectors, allowing for the assessment of the physiological impact of cosmetic or nutraceutical candidates during the early development phase. This approach supports environments where animal-free testing is essential and emphasizes the importance of understanding human biology in product development.

Komed Health offers a secure messaging platform designed to enhance communication among medical teams and between healthcare professionals and patients. This application streamlines and organizes real-time communication, replacing traditional methods like phones, pagers, and emails. It integrates seamlessly with existing clinical systems, facilitating integrated care pathways and enabling better decision-making by allowing physicians and nurses to access and share vital medical information at the point of care. The company collaborates closely with healthcare providers to develop features that cater specifically to the needs of modern healthcare professionals and workflows, aiming to improve care delivery through efficient and intelligent communication.

IbtiCare specializes in advanced antibacterial technology that utilizes Physical Vapor Deposition (PVD) to create coatings with nanoparticles that render surfaces antibacterial. This innovative solution effectively targets and eliminates a broad spectrum of dangerous bacteria, including those resistant to conventional drugs. The technology is designed to be fast-reactive, durable, and stable, ensuring long-lasting protection for various surfaces. IbtiCare's antibacterial solution has successfully passed clinical trials and has received validation from leaders in the healthcare sector, positioning it as a superior alternative to traditional antibacterial methods. The company's mission is to combat bacterial infections and enhance safety across multiple environments.

Odne is a medtech startup based in Renens, Switzerland, specializing in innovative implant technology for endodontics. Founded in 2018, the company focuses on the development of light-active medical fillers that facilitate the creation of implants directly within the body through a minimally invasive approach. This technology allows physicians to perform surgeries using an access channel of less than half a millimeter in diameter, significantly reducing surgical time and enhancing patient outcomes. By providing elegant solutions for complex procedures, Odne aims to improve the efficiency and effectiveness of medical interventions in the field of endodontics.

Gnubiotics Sciences SA specializes in developing microbiome-modulating products aimed at nurturing, maintaining, and restoring microbiome diversity in humans and animals. Founded in 2016 and based in Epalinges, Switzerland, the company produces glycans and functional mimics of Human Milk Oligosaccharides (HMOs) for the consumer health market. Their flagship product, AMObiomeTM, is designed to enhance microbiome diversity and promote lifelong gut health. By replicating the natural structures found in breast milk, Gnubiotics aims to prevent infections and combat diet-induced obesity, while also addressing the growing demand for healthier food options. The company's innovative approach focuses on supporting immune systems and overall well-being through natural microbiome modulation.

SensArs is a medical equipment manufacturing company specializing in neuromodulation technology aimed at treating diabetic neuropathy. The company has developed an innovative implantable neurostimulator electrode designed to restore sensory feedback by delivering precise electrical impulses to the nerve fibers that transmit pain signals. This technology not only assists healthcare providers in enhancing patient functionality but also offers a long-term solution for pain management. SensArs' flagship system, SENSY, is particularly beneficial for patients with amputations or nerve damage, as it helps to restore natural sensations in their feet.